Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Bexobrutideg · NX-5948

Small molecule (Molecular glue degrader) · Degrader of Bruton's tyrosine kinase (BTK) · developed by Nurix Therapeutics

Phase 3 Most advanced trial
NRIX Developer
1 Registered trials

What is Bexobrutideg?

Bexobrutideg (NX-5948) is an orally bioavailable chimeric targeting molecule that links a cereblon-binding moiety to a BTK-binding moiety. It recruits the CRL4-CRBN E3 ubiquitin ligase to BTK, driving its ubiquitination and proteasomal degradation. It is being studied in B-cell lymphoma, chronic lymphocytic leukemia and small lymphocytic lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NX-5948
Drug type
Small molecule (Molecular glue degrader)
Targets
Bruton's tyrosine kinase (BTK), cereblon (CRBN) (binding partner it blocks)
Mechanism
Degrader of Bruton's tyrosine kinase (BTK)
Pathways
B-cell receptor signaling, BTK-mediated survival signaling, CRL4-CRBN E3 ubiquitin ligase-mediated ubiquitination and proteasomal degradatio
Therapy area
Oncology
Developer
Nurix Therapeutics, Inc. (NRIX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
HVD6HGW6JD

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07516093 Phase 3 B-cell Lymphoma Recruiting NRIX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

B-cell LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Other drugs acting on BTK

More from Nurix Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NRIX page.

Follow NRIX, the company behind Bexobrutideg

See NRIX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NRIX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.